Methods: Morphologic evaluation, flow cytometry immunophenotypic studies, nanofluidics-based qualitative multiplex reverse transcriptase polymerase chain reaction, Sanger sequencing, and next-generation sequencing-based mutational hotspot analysis of 53 genes were performed on bone marrow biopsy and aspirate samples.
Results: Flow cytometry immunophenotypic analysis showed 0.6% CD34þ blasts with an abnormal immunophenotype: CD13 increased, CD33þ, CD38 decreased, CD117 increased, and CD123 increased.
Conclusions:
The acquisition of new phenotypic aberrancies in myeloblasts as detected by flow cytometry immunophenotypic studies might be a harbinger of impending myelodysplastic syndrome or acute myeloid leukemia in a patient with familial platelet disorder with propensity to myeloid malignancy.
Familial platelet disorder with propensity to myeloid malignancy (FPD/MM; OMIM 601399) is a rare autosomal dominant disease caused by germline heterozygous mutations in Runt-related transcription factor 1 (RUNX1). 1 Approximately 40 family pedigrees with FPD/MM have been described to date, but the frequency of this disorder is most likely underestimated. FPD/MM is characterized by inherited thrombocytopenia, normal platelet size, platelet functional defects, and an increased risk of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Thrombocytopenia is usually mild to moderate, but bleeding tends to be more severe than expected (based on the degree of thrombocytopenia) due to platelet dysfunction. Only a proportion of affected individuals develops MDS or AML, and as of today, it is impossible to predict who will develop MDS or AML and when. Here, we describe a population of aberrant myeloid precursors detected by flow cytometry immunophenotypic analysis in an asymptomatic man with FPD/MM. she required platelet transfusions infrequently, mostly for surgical procedures. The CBC of the patient we are reporting showed the following: hemoglobin, 140 g/L (normal range, 140-180 g/L); mean corpuscular volume, 89 fL (normal range, 82-98 fL); WBC count, 6.5 Â 10 9 /L (normal range, 4-11 Â 10 9 /L); platelet count, 92 Â 10 9 /L (normal range, 140-440 Â 10 9 /L); and mean platelet volume, 9.5 fL (normal range, 4-10.4 fL). A peripheral blood smear showed decreased numbers of platelets with adequate granularity. Erythrocytes and WBCs were morphologically unremarkable, and no blasts were identified. Twenty-one months later, at last clinical follow-up, the patient had a platelet count of 104 Â 10 9 /L, and he remained asymptomatic.
Materials and Methods

Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue blocks were cut in 4-mm-thick sections and processed with heat-induced epitope retrieval. 3,3
0 -Diaminobenzidine was used as a chromogen. Staining was performed in an automated immunostainer (Ventana Medical Systems, Tucson, AZ). Assessed antibodies against the following antigens were CD34 (MY10, 1:40; BD Biosciences, Franklin Lakes, NJ) and CD61 (2F2, 1:100; Cell Marque, Rocklin, CA).
Flow Cytometry Immunophenotypic Studies
Bone marrow aspirate samples were collected in EDTA anticoagulant and processed within 24 hours of collection. After incubation with monoclonal antibodies for 10 minutes at 4 C, erythrocytes were lysed with ammonium chloride (PharmLyse; BD Biosciences, San Diego, CA) at room temperature for 10 minutes using a standard lyse/wash technique. Samples were acquired on FACSCanto II instruments (BD Biosciences). Antibody panels are shown in Table 1 . A total of 200,000 events were acquired. Data were analyzed using FCS Express software (De Novo Software, Los Angeles, CA). Major cell populations were defined by CD45/SSC (side scatter) characteristics. Aberrancies of myeloblasts were assessed on CD34þCD10À/ CD19-myeloid precursors. The normal ranges of intensity of antigen expressions and the percentage of expressions were established on 30 healthy controls (with no hematopoietic neoplasm and with a normal CBC) in our previous study, and the flow cytometric immunophenotypic assay was validated in cytopenic patients without MDS and those with chronic myelomonocytic leukemia. 2 For antigens normally not expressed or only partially expressed, the expressions were measured as a percentage, whereas for antigens normally highly expressed, such as CD38, CD117, CD123, CD34, CD45, and CD13, the levels of antigen expressions were measured by mean fluorescence intensity. "Alterations" were two standard deviations from normal controls, also confirmed by at least one-third of log scale changes.
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Conventional Cytogenetics
Conventional G-band karyotype analysis was performed on bone marrow aspirate specimens as described previously. 4 Karyotype was written following the 2013 International System for Human Cytogenetics Nomenclature. 5 
Next-Generation Sequencing
Next-generation sequencing to assess mutational hotspots in 53 genes (ABL1, AKT1, ALK, APC, ATM, BRAF, CDKN2A, CHD1, CSF1R, CTNNB1, DNMT3A, EGFR, ERBB2, ERBB4, EZH2, FBXW7, FGFR1, FGFR2, FGFR3, FLT3, GNA11, GNAQ, GNAS, HNF1A, HRAS, IDH1, IDH2, JAK2, JAK3, KDR, KIT, KLHL6, KRAS, MET, MLH1, MPL, NOTCH1, NPM1, NRAS, PDGFRA, PIK3CA, PTEN, PTPN11, RB1, RET, SMAD4, SMARCB1, SMO, SRC, STK11, TP53, VHL, and XPO1) was performed on bone marrow aspirate specimens as described previously using a MiSeq sequencer (Illumina, San Diego, CA). 6 
Nanofluidics
Nanofluidics-based qualitative multiplex reverse transcriptase polymerase chain reaction (RT-PCR) was performed on bone marrow aspirate specimens (Fluidigm, San Francisco, CA). It is designed to detect t(8;21)(q22;q22); RUNX1-RUNX1T1, inv(16)(p13.1q22) or t(16;16)(p13.1q22); CBFb-MYH11, t(15;17)(q22;q12); PML-RARA, t(9;22)(q34;q11.2); BCR-ABL1, t(12;21)(p13;q22); ETV6-RUNX1, t(1;19)(q23; p13.3); E2A-PBX1, t(4;11)(q21;q23); MLL-AF4, and t(6;9) (p23;q34); DEK-NUP214.
Sanger Sequencing
Sanger sequencing was performed at Baylor College of Medicine (Houston, TX). 
Results
Morphologic Findings
Bone marrow biopsy specimens showed a cellular (40%-50%) bone marrow. Megakaryocytes were increased (10/ high-power field) with small monolobated forms Image 1A . Granulocytic and erythroid precursors showed complete maturation. Reticulin and trichrome stains demonstrated slightly increased reticulin fibrosis (MF-1 by European Consensus on grading bone marrow fibrosis). 7 Bone marrow aspirate smears showed rare dysplastic megakaryocytes with separated nuclear lobes Image 1B . The granulocytic and precursors showed complete maturation without dysplasia. Blasts were not increased. Iron stain showed decreased storage iron (1þ of 4).
Immunohistochemistry and Flow Cytometry Immunophenotypic Studies
Immunohistochemical analysis was performed on the bone marrow biopsy specimens. The anti-CD61 antibody showed dysplastic small monolobated megakaryocytes Image 1C . Anti-CD34 stain showed 1% of CD34þ blasts Image 1 Representative images of bone marrow biopsy and aspiration specimens. A, Bone marrow biopsy specimen shows adequate cellularity for age and increased number of small, hypolobated megakaryocytes (H&E, Â400). B, Bone marrow aspiration smear shows a small, hypolobated megakaryocyte (Giemsa, Â1,000). C, Anti-CD61 stain on bone marrow biopsy section highlights increased number of small, hypolobated megakaryocytes (Â400). D, Anti-CD34 stain on bone marrow biopsy section shows rare CD34þ immature cells (Â400).
Image 1D . Flow cytometry immunophenotypic studies performed using bone marrow aspirate material showed 0.6% CD34þ blasts with an abnormal immunophenotype: CD13 increased, CD33þ, CD38 decreased, CD117 increased, and CD123 increased Image 2 . No monoclonal B cells or aberrant T cells were detected.
Cytogenetic and Molecular Studies
Conventional cytogenetic analysis detected a normal male karyotype in 20 metaphases. Next-generation sequencing did not detect any mutations. Nanofluidics-based qualitative multiplex RT-PCR was negative. Sanger sequencing detected a germline heterozygous c.836G>A (p.W279X) mutation in the RUNX1 gene, which was identical to the mutation identified previously in his daughter.
Discussion
RUNX1, formerly known as AML1 and CBFA2, is located at chromosome locus 21q22.12. RUNX1 protein has a highly conserved Runt homology domain (RHD) at the Nterminal and a transactivation domain at the C-terminal. The RHD domain mediates DNA binding and heterodimerization with CBFb, which enhances the affinity of RUNX1 Of note, thrombocytopenia is not a requisite for diagnosis, and many patients do not have a history of bleeding. 10, 19 However, when a patient has a bleeding tendency, the degree of bleeding can be disproportionate to the level of thrombocytopenia because of qualitative defects in platelets such as decreased adenosine diphosphate (ADP) and serotonin and a decreased number of dense granules. 20 Platelet aggregation tests often show abnormal results in response to arachidonic acid, collagen, and epinephrine, but platelet aggregation in response to ADP and ristocetin is normal. 17, 20 The underlying mechanism of qualitative and quantitative platelet defects in FDP/MM is incompletely understood. Available data demonstrate that RUNX1 mutation is associated with impaired agonist-induced platelet myosin light chain phosphorylation and receptor-mediated GPIIb-IIIa activation. 21 Myosin light chain phosphorylation takes part in platelet shape change and platelet granule secretion upon activation. In one patient reported, there was a 77-fold downregulation of one of the myosin light chain genes, MYL9, which is a target of RUNX1. 22, 23 Quantitative platelet defects in patients with FPD/MM can be partially explained by decreased expression of the MPL receptor, impaired thrombopoietin-induced signaling, and impaired megakaryocyte maturation with proplatelet formation. 24, 25 The bone marrow of patients with FDP/MM generally shows mildly decreased megakaryocytes with a predominance of immature forms. The immature megakaryocytes usually show a high nuclear-to-cytoplasm ratio, strongly basophilic cytoplasm, and poorly lobulated nuclei. In contrast, erythropoiesis and granulopoiesis are completely normal with no bone marrow fibrosis unless MDS or AML develops.
Recently Mutations causing haploinsufficiency are more commonly reported than ones with a dominant-negative effect. 1, 27, 28 Interestingly, RUNX1 mutations with a dominant-negative effect are more frequently associated with subsequent leukemia than mutations associated with haploinsufficiency. 28 Patients with FPD/MM have an increased risk of myeloid neoplasms, including acute myeloid leukemia, myelodysplastic syndromes, and chronic myelomonocytic leukemia. 29 The morphologic types of acute myeloid leukemia, as designated using the French-American-British group terminology, include M1, M2, M4, and M5. The frequency of myeloid malignancies in patients with FDP/MM has been reported to range from 20% to 65%. 17, 18 Rare patients who developed T-lymphoblastic leukemia and diffuse large Bcell lymphoma also have been reported rarely. 14, 18, 26, 30 The median patient age when they develop leukemia is 37 years, but children as young as 6 years are reported. 26 Germline RUNX1 mutation alone is insufficient for development of leukemia; a second hit is required. 31 Bluteau et al 25 showed
that RUNX1 mutations increase the clonogenic potential of There are no established guidelines for the management of patients with FDP/MM. When bleeding tendency is severe, patients are treated similarly to patients with other platelet function disorders. When AML or MDS develops, patients are treated with chemotherapy or stem cell transplantation. Prior studies have shown that the same mutation can be detected in siblings who are being evaluated as potential transplant donors. 9, 26 Although most of the reported RUNX1 mutations are located in exons 3 to 8, whole or partial hemizygous RUNX1 deletion and intragenic gene duplications have also been described. These latter alterations can be missed by Sanger sequencing and require further genetic assessment of copy number abnormalities using a single-nucleotide polymorphism array or array comparative genomic hybridization. 8 It is recommended that screening for germline RUNX1 mutation be performed when there is a bleeding tendency in a family, unexplained mild thrombocytopenia with normal platelet size in combination with abnormal platelet aggregation studies, or isolated dysplastic changes in megakaryocytes.
To our knowledge, the detection of aberrant myeloblasts by flow cytometry immunophenotypic analysis has not been reported previously in asymptomatic patients with FPD/MM. Our group has demonstrated high sensitivity and specificity of flow cytometry immunophenotypic studies for the detection of aberrant myeloblasts in patients with MDS. 2 Since only a proportion of patients with FPD/MM develops MDS or AML, and it can take many years to do so, there is a desperate need for better tools to predict which patients with FDP/MM may develop MDS or AML. It is conceivable that a new, second clone emerging after a "second genetic hit" and slowly progressing into overt MDS or AML also could be detected by flow cytometry immunophenotypic studies at an asymptomatic or oligosymptomatic phase, well in advance of the onset of clinically relevant MDS or AML. If it is shown that the presence of clonal progression indicates that patients are doomed to develop AML or MDS in the near future, these patients might benefit from aggressive therapeutic intervention. However, prospective studies are needed to address this issue.
